Skip to content

PROphylaxis for Venous ThromboEmbolism in Severe Traumatic Brain Injury (PROTEST)

Traumatic Brain Injury

This is a phase III, multi-centre, double blind, randomized controlled trial of patients with traumatic brain injury (TBI).

null

Participation Requirements

  • Sex:

    ALL
  • Eligible Ages:

    18 and up

Participation Criteria

Inclusion Criteria

The pragmatic nature of this study seeks to include all consecutive patients presenting with significant TBI, regardless of whether ICB is evident at presentation. Inclusion criteria are the following:

i) Patients with severe TBI defined as GCS of ≤8, or

ii) Patients with moderate TBI defined as GCS = 9-12, admitted to ICU, with at least some ICB present on initial CT scan and any of the following:

1. Requiring invasive mechanical ventilation at the time of screening
2. Increased ICB on repeat CT scan compared to initial CT scan

iii) Upon randomization the patient will be able to receive the first dose of study drug in the first 3 calendar days from the time of injury

iv) ≥ 18 years of age

Exclusion Criteria

All participants meeting any of the following exclusion criteria at baseline will be excluded from participation in this study:

i) Known Hypersensitivity to FRAGMIN (Dalteparin), or its constituents including benzyl alcohol or to other low molecular weight heparins and/or heparins or pork products

ii) Known history of confirmed or suspected immunologically-mediated heparin-induced thrombocytopenia (delayed-onset severe thrombocytopenia), and/or in patients with a known history of a positive in vitro platelet-aggregation test in the presence of FRAGMIN (Dalteparin) is positive

iii) Known septic endocarditis

iv) Uncontrollable active bleeding

v) Known major blood clotting disorders

vi) Known acute gastroduodenal ulcer (with active bleeding)

vii) Severe uncontrolled hypertension (i.e. BP\>210 despite medications)

viii) Known diabetic or hemorrhagic retinopathy

ix) Anticipated to be unable to receive SCD on at least one lower extremity due to nature of injuries for duration of intervention period

x) Presence of another confounding factor that can adequately explain the poor GCS at time of presentation (e.g. drug toxicity, seizure)

xi) Known presence of irreversible coagulopathies

xii) Known Pregnancy

xiii) Participants extremely low weight (\<45 kg), or extremely high weight (\>120kg)

xiv) Not expected to survive more than 48 hours from admission

Study Location

Vancouver General Hospital
Vancouver General Hospital
Vancouver, British Columbia
Canada

Contact Study Team

Primary Contact

Rebecca Grey

[email protected]
Backup Contact

Donald Griesdale, MD, MPH, FRCPC

The Ottawa Hospital
The Ottawa Hospital
Ottawa, Ontario
Canada

Contact Study Team

Primary Contact

Rebecca Porteous

[email protected]
Backup Contact

Sydney Mietzitis

[email protected]
Backup Contact

Shane English, MD, MSc, FRCPC

University of Alberta Hospital
University of Alberta Hospital
Edmonton, Alberta
Canada

Contact Study Team

Backup Contact

Jim Kutsogiannis, MD, MHS, FRCPC

Backup Contact

Tayne Hewer

[email protected]
Primary Contact

Patrica Thompson

[email protected]
Kingston General Hospital
Kingston General Hospital
Kingston, Ontario
Canada

Contact Study Team

Backup Contact

Gordon Boyd, MD, PhD, FRCPC

Primary Contact

Tracy Boyd

[email protected]
Royal University Hospital
Royal University Hospital
Saskatoon, Saskatchewan
Canada

Contact Study Team

Backup Contact

Gary Hunter, MD, FRCPC, CSCN (EEG)

Primary Contact

Emily Junk

[email protected]
Foothills Medical Centre
Foothills Medical Centre
Calgary, Alberta
Canada

Contact Study Team

Primary Contact

Olesya Dmitrieva

[email protected]
Backup Contact

Andreas Kramer, MD

Queen Elizabeth II Health Sciences Centre
Queen Elizabeth II Health Sciences Centre
Halifax, Nova Scotia
Canada

Contact Study Team

Backup Contact

Lisa Julien

[email protected]
Primary Contact

Laura-Lee Magennis

[email protected]
Backup Contact

Sean Christie, MD, FRCSC

Backup Contact

Laurel Murphy, MD

Sunnybrook Health Science Centre
Sunnybrook Health Science Centre
Toronto, Ontario
Canada

Contact Study Team

Backup Contact

Damon Scales, MD, PhD, FRCPC

Primary Contact

Farhad Pirouzmand, MD, MSc, FRCSC

Royal Alexandra Hospital
Royal Alexandra Hospital
Edmonton, Alberta
Canada

Contact Study Team

Backup Contact

Jim Kutsogiannis, MD, MHS, FRCPC

Primary Contact

Patrica Thompson

[email protected]
Backup Contact

Tayne Hewer

[email protected]
Hamilton Health Sciences Centre
Hamilton Health Sciences Centre
Hamilton, Ontario
Canada

Contact Study Team

Backup Contact

Paul Engels, MD

Primary Contact

Amanda Martyniuk

[email protected]
Backup Contact

Sunjay Sharma, MD, MSc, FRCSC, FACS

Unity Health Toronto
Unity Health Toronto
Toronto, Ontario
Canada

Contact Study Team

Backup Contact

Michael Cusimano, MD, MHPE, FRCS, PhD

Primary Contact

Marlene Santos, MD, MSc

[email protected]
Study Sponsored By
Sunnybrook Health Sciences Centre
Participants Required
More Information
Study ID: NCT03559114